Loading tape…Loading tape…
GILD
GILD
GILD
GILD NASDAQ
Archer Investment Corp has established a position in Gilead Sciences, Inc., as reported by defenseworld.net. The company currently has a market capitalization of approximately $187.47 billion and generated $29.442 billion in full-year revenue. Gilead also demonstrates a free cash flow yield of 7.04%, alongside a trailing EPS of -2.61 and a P/E ratio of -58.08.
Based on defenseworld.netArcher Investment Corp Takes Position in Gilead Sciences, Inc. $GILD
BNP Paribas Purchases 20,329 Shares of Gilead Sciences, Inc. $GILD
Beacon Pointe Advisors LLC Reduces Holdings in Gilead Sciences, Inc. $GILD
Gilead Wins FDA Nod for Bixlenvo in Adults Living With HIV Infection
Bamco Inc. NY Sells 12,000 Shares of Gilead Sciences, Inc. $GILD
US FDA approves Gilead's once-daily combination pill for HIV treatment
Revenue & Net Income (5Y)
EPS & Growth (5Y)
Free Cash Flow (5Y)
Capital Returns
Operating & Net Margin (5Y)
CapEx vs. Free Cash Flow (5Y)
Capital Allocation (5Y)
R&D and SG&A Intensity (5Y)
EBITDA (5Y)
Cost of Revenue (5Y)
Market Cap (5Y)
Ask Stonks with professional market data, charts beside chat, and your portfolio context.
Tape shows delayed public market data. Not investment advice.